Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Straus, David J.; Długosz-Danecka, Monika; Connors, Joseph M.; Алексеев, С. М.; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J.; Bartlett, Nancy L.; Walewski, Jan; Ramchandren, Radhakrishnan; Zinzani, Pier Luigi; Hutchings, Martin; Muñoz, Javier; Lee, Hun Ju; Kim, Won Seog; Advani, Ranjana H.; Ansell, Stephen M.; Younes, Anas; Gallamini, Andrea; Liu, Rachael; Little, Meredith; Fenton, Keenan; Fanale, Michelle A.; Radford, John

doi:10.1016/s2352-3026(21)00102-2

Cited by 98 publications

(107 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BVIN can occur in patients with HL receiving BV as either a single agent in cases of R/R cHL [ 3 ] or as consolidation therapy after ASCT [ 6 , 7 ], or in combination with chemotherapy as salvage therapy before ASCT [ 16 , 17 ] or in newly diagnosed HL patients [ 4 , 5 ]. Reported overall rates of PN in adult patients with R/R HL range from 9 to 73% ( Table 1 ).…”

Section: Epidemiology Of Bvinmentioning

confidence: 99%

“…Additionally, high rates of PN have also been observed in newly diagnosed scenarios. In ECHELON-1—a randomised, open-labelled, controlled trial in frontline therapy in advanced HL where BV in combination with AVD was compared to ABVD—PN was observed in 67% of patients, with a high incidence of moderate to severe events (20% grade 2, 11% grade 3) [ 4 , 5 ]. Of note, the rate of PN in the control arm (vinblastine-containing regimen without BV) of this trial was 43%, with 2% as grade 3, suggesting a cumulative/summatory effect of a two-agent combination with a known neurotoxic profile.…”

Section: Epidemiology Of Bvinmentioning

confidence: 99%

“…The recommended dose-and-administration schedule for BV in patients with either relapsed classical HL or HL with a high risk of progression after auto-HSCT is an intravenous infusion of 1.8 mg/kg for 30 min every three weeks. For previously untreated patients with classical HL receiving chemotherapy, the recommended dose-and-administration schedule for BV is 1.2 mg/kg up to a total of 120 mg every two weeks for a maximum of 12 doses [ 4 , 5 ]. For re-treatment, the starting BV dose should be either 1.8 mg/kg or the last tolerated dose [ 62 ].…”

Section: Early Diagnosis and Management Of Bvinmentioning

confidence: 99%

“…Brentuximab vedotin (BV) (Adcetris ® , Seagen, Inc., Bothell, WA, USA) is the first anti-CD30 antibody-drug conjugate (ADC) to be approved by both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat patients with R/R HL [ 3 ]. BV has received approval for different cHL treatment settings, including newly diagnosed patients [ 4 , 5 ], and as consolidation treatment after autologous stem cell transplantations (ASCT) [ 6 , 7 ]. In addition to cHL, BV has shown to be highly effective in other CD30-positive neoplasms, such as peripheral T-cell lymphomas (PTCL), systemic anaplastic large cell lymphoma (sALCL), primary cutaneous anaplastic large cell lymphoma (pcALCL), and CD30-expressing mycosis fungoides (MF) [ 8 , 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy

Velasco

Domingo‐Domenech

Sureda

2021

Cancers

View full text Add to dashboard Cite

Brentuximab vedotin (BV) is an anti-CD30 antibody–drug conjugate approved to treat classical Hodgkin lymphoma (HL). BV-induced peripheral neurotoxicity (BVIN) is one of the greatest concerns for haematologists treating HL for several reasons. First, BVIN is highly frequent. Most patients receiving BV will experience some degree of BVIN, resulting in the primary reason for dose modification or discontinuation of HL therapy. Second, BV produces sensory, motor, and/or autonomic peripheral nerve dysfunction, which can present as severe, disabling forms of BVIN—predominantly motor—in some patients. Third, although largely reversible, BVIN may persist months or years after treatment and thereby become a major issue in HL survivorship. BVIN may, therefore, negatively affect the quality of life and work-life of often young patients with HL, in whom long-term survival is expected. Currently, the only strategy for BVIN includes dose adjustments and treatment discontinuation; however, this could interfere with LH therapy efficacy. In this setting, early recognition and adequate management of BVIN are critical in improving clinical outcomes. Careful neurologic monitoring may allow accurate diagnoses and gradation of ongoing forms of BVIN presentation. This review analysed current, available data on epidemiology, pathophysiology, patient- and treatment-related risk factors, clinical and neurophysiologic phenotypes, and management in patients with HL. Furthermore, this review specifically addresses limitations posed by BVIN assessments in clinical practice and provides skills and tools to improve neurologic assessments in these patients. Integrating this neurotoxic drug in clinical practice requires a multidisciplinary approach to avoid or minimise neurotoxicity burden in survivors of HL.

show abstract

Section: Epidemiology Of Bvinmentioning

confidence: 99%

Section: Epidemiology Of Bvinmentioning

confidence: 99%

Section: Early Diagnosis and Management Of Bvinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy

Velasco

Domingo‐Domenech

Sureda

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition to ABVD, BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) has become an option, based on the results of the ECHLON-1 trial. 5,6 Brentuximab vedotin (BV), which is an antibody drug conjugate, replaced bleomycin to reduce the risk of significant lung injury. A more intensive chemotherapy regimen, escalated BEACOPP, is often used in Germany, with similar results to ABVD.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Lin¹,

Schnitter²,

Gordon³

2022

ITT

View full text Add to dashboard Cite

Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system. Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma. The two most commonly used checkpoint inhibitors are pembrolizumab and nivolumab, both FDA approved as third-line therapy. There is increasing interest in the use of checkpoint inhibitors with combination chemotherapy or with other targeted agents in the second-line or even frontline setting. In this review, we will highlight the clinical trials that led to approvals of checkpoint inhibitors for Hodgkin lymphoma.

show abstract

Targeting CD 30 in Lymphoid Neoplasms

Pro

2024

Precision Cancer Therapies Vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice

View full text Add to dashboard Cite

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Cited by 98 publications

References 24 publications

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Targeting CD 30 in Lymphoid Neoplasms

Contact Info

Product

Resources

About